Financial results (Q3 FY2022) - QoQ comparison

The company has reported a total income of Rs. 4194.99 crore during the period ended December 31, 2021 as compared to Rs. 4164.14 crore during the period ended September 30, 2021.

The company has posted net profit of Rs. 545.52 crore for the period ended December 31, 2021 as against a loss of Rs. -2098.04 crore for the period ended September 30, 2021.

Financial results (Q3 FY2022) - YoY comparison

The company has reported a total income of Rs. 4194.99 crore during the period ended December 31, 2021 as compared to Rs.4038.53 crore during the period ended December 31, 2020.

The company has posted a net profit of Rs.545.52 crore for the period ended December 31, 2021 as against a net profit of Rs.438.25 crore for the period ended December 31, 2020.

Financial results (nine-month ended FY2022) - YoY comparison

The company has reported a total income of Rs.12,649.30 crore during the nine-month period ended December 31, 2021 as compared to Rs.11469.25 crore during the nine-month period ended December 31, 2020.

The company has posted a loss of Rs.-1010.06 crore for the nine-month period ended December 31, 2021 as against net profit of Rs.756.17 crore for the nine-month period ended December 31, 2020.

Commenting on the results, Nilesh Gupta, Managing Director, Lupin Limited said, “We are on the path of sustained growth across markets. Our inhalation portfolio continues to build share in the U.S. and helped register double-digit growth sequentially, despite pricing and demand challenges on seasonal products. The inflationary environment has impacted margins, but we remain focussed on margin and EBIDTA improvement as we deliver on key product launches, cost optimization and improving efficiencies, especially by H2 FY23”